NCT02558764

Brief Summary

Advances in surgical techniques and immunosuppression (IS) have led to an appreciable reduction in postoperative complications following kidney transplantation. However, surgical site events (SSE) including surgical site infections (SSI) and other wound complications are still very common and they can limit these improved outcomes and result in prolonged hospitalization, hospital readmission and reoperation, consequently increasing overall transplant cost. Negative pressure wound therapy (NPWT) is a concept introduced initially to assist in the treatment of chronic open wounds. This technique uses a negative pressure unit and specific dressings that help to hold the incision edges together, redistribute lateral tension, reduce edema, stimulate perfusion and protect the surgical site from external infectious sources. Thus, it provides faster wound healing and shortens hospital stay. Recently, there has been growing interest in using portable NPWT devices on closed incisions after surgery to prevent potential SSI and other wound complications in high-risk patients. Investigations regarding this technique in various surgical settings have shown that it can reduce the risk of SSI and other wound complications. These studies concluded that any patient undergoing transplantation should be considered as 'high-risk' and should receive this treatment. To date, no studies are reported in literature exploring the effects of preventive use of portable NPWT devices on surgical wounds in the setting of organ transplantation. The aim of our study is to compare a portable NPWT device (PICO, Smith \& Nephew, London UK) to conventional gauze dressings in patients undergoing kidney transplantation (KT) surgery.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Dec 2016

Shorter than P25 for not_applicable

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 18, 2015

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 24, 2015

Completed
1.2 years until next milestone

Study Start

First participant enrolled

December 7, 2016

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 10, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 10, 2017

Completed
Last Updated

October 28, 2022

Status Verified

September 1, 2015

Enrollment Period

3 months

First QC Date

September 18, 2015

Last Update Submit

October 26, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • post-kidney transplant wound complication rates

    Primary outcome of this study will be 'post- KT wound complication (superficial wound dehiscence, evisceration, seromas, incisional hernias, wound infections and wound necrosis) rates'. The potential relation of these complications with PICO application will be assessed.

    up to 12 months

Study Arms (2)

Control

NO INTERVENTION

No intervention; basic wound contact absorbent dressings will be used as per current standard of care.

PICO

OTHER

PICO device will be used for prevention of wound complications. This is a portable negative pressure wound treatment device. Patients will have the device for 7 days after undergoing kidney transplant surgery.

Device: portable (pocket) negative pressure wound treatment device

Interventions

PICO device will be applied to the surgical wounds of kidney transplant patients who are enrolled in the PICO group. These patients will have this device on for 7 days after undergoing kidney transplant surgery.

Also known as: PICO, Smith & Nephew, London UK
PICO

Eligibility Criteria

Age19 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult (≥18 years of age)
  • female/male cadaveric kidney transplant recipients who have a preoperative order for standard induction immunosuppression protocol (basiliximab and methylprednisolone) and give written consent will be included in this study.

You may not qualify if:

  • Patients who have a pre-operative order for a non-standard induction immunosuppression regimen
  • Patients deemed not capable to take care for the PICO device
  • Multi-organ transplant recipients (simultaneous liver-kidney transplant, simultaneous kidney-pancreas transplant)
  • Dual KT recipients (simultaneous kidney-kidney transplant)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 18, 2015

First Posted

September 24, 2015

Study Start

December 7, 2016

Primary Completion

March 10, 2017

Study Completion

March 10, 2017

Last Updated

October 28, 2022

Record last verified: 2015-09